SOURCE: Cleveland BioLabs, Inc.

February 20, 2008 11:23 ET

Cleveland BioLabs CEO to Present at 3rd Annual Stem Cell Summit in New York City

BUFFALO, NY--(Marketwire - February 20, 2008) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company is scheduled to present at the 3rd Annual Stem Cell Summit in New York City on Tuesday, February 26, 2008.

The Annual Stem Cell Summit is organized and produced by RRY Publications and Robin Young Consulting. This year's Summit will feature more than 50 speakers, including a panel of stem cell patients. The goal of the Summit is to bring together investors, industry executives, practitioners and analysts to learn about investment opportunities in the stem cell marketplace, groundbreaking stem cell products physicians are using today, and the growing market potential in terms of revenues. For additional information or to register, please visit www.stemcellsummit.com.

Michael Fonstein, Ph.D., President and Chief Executive Officer of Cleveland BioLabs, will give a brief presentation on the Company's Protectan CBLB612 compound at 10:44 a.m. ET on February 26.

Protectan CBLB612 is a modified lipopeptide mycoplasma that acts as a powerful stimulator and mobilizer of hematopoietic (bone marrow/blood production) stem cells (HSC) to peripheral blood. Potential applications for CBLB612 include accelerated hematopoietic recovery during chemotherapy, as well as during donor preparation for bone marrow transplantation.

Direct comparisons of Protectan CBLB612 and the market leading drug used for stimulation of blood regeneration, G-CSF, demonstrated stronger efficacy of CBLB612 as a propagator and mobilizer of HSC in peripheral blood. CBLB612's unprecedented strength as a stem cell stimulator was further demonstrated by the outcome of its combined use with G-CSF and AMD3100 (a drug candidate emerging as a stem cell mobilizer), where the addition of CBLB612 resulted in eight to ten times higher yields of HSC in peripheral blood in comparison with the standard protocol.

With efficacy and non-GLP safety already studied in mice and monkeys, CBLB612 entered formal pre-clinical safety and manufacturing development in February 2008. Its first human trials are projected for 2009.

About Cleveland BioLabs, Inc.

Cleveland BioLabs, Inc. is a drug discovery and development company leveraging its proprietary discoveries about programmed cell death to treat cancer and protect normal tissues from exposure to radiation and other stresses. The Company has strategic partnerships with the Cleveland Clinic, Roswell Park Cancer Institute, ChemBridge Corporation and the Armed Forces Radiobiology Research Institute. To learn more about Cleveland BioLabs, Inc., please visit the company's website at http://www.cbiolabs.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Some of the factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's periodic filings with the Securities and Exchange Commission.

Contact Information

  • Contacts:
    Rachel Levine
    Director Corporate Development & Communications
    Cleveland BioLabs, Inc.
    T: (646) 284-9439
    E: rlevine@cbiolabs.com